Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Abstract Background Rasagiline is a monoamine oxidase-B inhibitor used for Parkinson’s disease (PD) treatment, but its effectiveness on Chinese patients is unclear. This study aimed to evaluate the efficacy and safety of rasagiline monotherapy in Chinese patients with early PD. Methods A 26-weeks, r...

Full description

Bibliographic Details
Main Authors: Zhenxin Zhang, Jian Wang, Shengdi Chen, Chunfeng Liu, Baorong Zhang, Rong Peng, Shenggang Sun, Xiangru Sun, Gang Zhao, Qiumin Qu, Yansheng Li, Suiqiang Zhu, Xiaoping Pan, Ming Shao, Yanping Wang
Format: Article
Language:English
Published: BMC 2018-12-01
Series:Translational Neurodegeneration
Subjects:
Parkinson’s disease
Monoamine oxidase inhibitor
Rasagiline
Monotherapy
China
Online Access:http://link.springer.com/article/10.1186/s40035-018-0137-5

Internet

http://link.springer.com/article/10.1186/s40035-018-0137-5

Similar Items